Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was downgraded by research analysts at Credit Suisse Group to a “hold” rating in a research report issued to clients and investors on Friday. They currently have a $485.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s target price points to a potential downside of 3.94% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Leerink Swann set a $448.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 28th. BTIG Research restated a “buy” rating and set a $460.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, March 20th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price target on the stock in a report on Thursday, April 27th. Vetr downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price target on the stock. in a report on Monday, April 24th. Finally, Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $375.00 to $484.00 in a report on Friday, May 5th. One research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $456.54.

Regeneron Pharmaceuticals (NASDAQ REGN) traded down 0.03% during mid-day trading on Friday, hitting $504.90. The stock had a trading volume of 608,260 shares. The firm’s 50-day moving average is $474.83 and its 200 day moving average is $400.97. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The stock has a market cap of $53.30 billion, a PE ratio of 61.12 and a beta of 1.67.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.42. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. Regeneron Pharmaceuticals’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.57 EPS. Equities research analysts expect that Regeneron Pharmaceuticals will post $12.73 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Credit Suisse Group Lowers Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Hold” was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/15/credit-suisse-group-lowers-regeneron-pharmaceuticals-inc-nasdaqregn-to-hold.html.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $482.55, for a total value of $482,550.00. Following the transaction, the director now directly owns 14,000 shares in the company, valued at $6,755,700. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael S. Brown sold 3,000 shares of the business’s stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $1,350,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,396 shares of company stock worth $28,484,734. 10.40% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in REGN. IFP Advisors Inc raised its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares during the period. Korea Investment CORP raised its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares during the period. Advisory Services Network LLC raised its position in Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares during the period. WFG Advisors LP raised its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,415 shares during the period. Finally, Alpha Windward LLC raised its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 34 shares during the period. Hedge funds and other institutional investors own 66.90% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.